Faron Pharmaceuticals Oy (FARN) Competitors GBX 168 +3.00 (+1.82%) (As of 12/20/2024 10:05 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlines FARN vs. ERGO, SLN, OXB, PRTC, HZD, VRP, ARIX, BVXP, AVCT, and 4BBShould you be buying Faron Pharmaceuticals Oy stock or one of its competitors? The main competitors of Faron Pharmaceuticals Oy include Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), Avacta Group (AVCT), and 4basebio (4BB). These companies are all part of the "biotechnology" industry. Faron Pharmaceuticals Oy vs. Ergomed Silence Therapeutics Oxford Biomedica PureTech Health Horizon Discovery Group plc (HZD.L) Verona Pharma plc (VRP.L) Arix Bioscience Bioventix Avacta Group 4basebio Faron Pharmaceuticals Oy (LON:FARN) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, community ranking, institutional ownership, profitability and media sentiment. Does the media refer more to FARN or ERGO? In the previous week, Faron Pharmaceuticals Oy's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score. Company Overall Sentiment Faron Pharmaceuticals Oy Neutral Ergomed Neutral Is FARN or ERGO more profitable? Ergomed has a net margin of 9.87% compared to Faron Pharmaceuticals Oy's net margin of 0.00%. Ergomed's return on equity of 18.08% beat Faron Pharmaceuticals Oy's return on equity.Company Net Margins Return on Equity Return on Assets Faron Pharmaceuticals OyN/A N/A -70.00% Ergomed 9.87%18.08%10.16% Do institutionals and insiders hold more shares of FARN or ERGO? 10.7% of Faron Pharmaceuticals Oy shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 31.8% of Faron Pharmaceuticals Oy shares are owned by insiders. Comparatively, 18.2% of Ergomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, FARN or ERGO? Faron Pharmaceuticals Oy has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Which has better valuation & earnings, FARN or ERGO? Ergomed has higher revenue and earnings than Faron Pharmaceuticals Oy. Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFaron Pharmaceuticals Oy-£725K-242.43-£31.61M-£0.32-525.00Ergomed£152.09M0.00£15M£0.29N/A Does the MarketBeat Community prefer FARN or ERGO? Faron Pharmaceuticals Oy received 75 more outperform votes than Ergomed when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 75.63% of users gave Ergomed an outperform vote. CompanyUnderperformOutperformFaron Pharmaceuticals OyOutperform Votes31777.51% Underperform Votes9222.49% ErgomedOutperform Votes24275.63% Underperform Votes7824.38% SummaryErgomed beats Faron Pharmaceuticals Oy on 9 of the 12 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Faron Pharmaceuticals Oy News Delivered to You Automatically Sign up to receive the latest news and ratings for FARN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FARN vs. The Competition Export to ExcelMetricFaron Pharmaceuticals OyBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£175.76M£164.65M£5.13B£1.80BDividend YieldN/A3.64%4.93%10.52%P/E Ratio-525.00115.5189.741,737.11Price / Sales-242.4318,239.951,115.29368,902.29Price / Cash20.0012.7542.8227.57Price / Book168.008.504.772.86Net Income-£31.61M-£20.67M£120.04M£154.29M7 Day Performance-1.18%-1.06%-1.92%-1.88%1 Month Performance17.07%136.63%11.46%17.06%1 Year Performance-45.81%137.52%30.52%28.21% Faron Pharmaceuticals Oy Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FARNFaron Pharmaceuticals OyN/AGBX 168+1.8%N/A-44.0%£175.76M£-725,000.00-525.0034ERGOErgomedN/AN/AN/AN/A£701.00M£152.09M4,641.386SLNSilence TherapeuticsN/AGBX 535-0.9%N/A+0.0%£480.35M£11.35M-11.01100News CoveragePositive NewsHigh Trading VolumeOXBOxford BiomedicaN/AGBX 423.50flatGBX 433.33+2.3%+115.4%£446.20M£97.28M-295.83891PRTCPureTech Health2.247 of 5 starsGBX 170+4.4%GBX 455+167.6%+0.3%£407.01M£3.33M-739.13300News CoverageHigh Trading VolumeHZDHorizon Discovery Group plc (HZD.L)N/AN/AN/A+0.0%£302.98M£54.63M-33.55416VRPVerona Pharma plc (VRP.L)N/AN/AN/A+0.0%£228MN/A-1.6822News CoverageGap UpARIXArix BioscienceN/AN/AN/A+17.4%£183.73M£14.16M1,290.919BVXPBioventixN/AGBX 3,475-0.7%N/A-24.1%£181.40M£13.60M2,135.1012AVCTAvacta GroupN/AGBX 45.75+6.4%N/A-58.2%£163.92M£22.62M-508.33120News CoverageNegative News4BB4basebioN/AGBX 1,210+2.1%N/A+83.3%£155.00M£311,000.00-1,551.28101Positive News Related Companies and Tools Related Companies Ergomed Alternatives Silence Therapeutics Alternatives Oxford Biomedica Alternatives PureTech Health Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Bioventix Alternatives Avacta Group Alternatives 4basebio Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:FARN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Faron Pharmaceuticals Oy Please log in to your account or sign up in order to add this asset to your watchlist. Share Faron Pharmaceuticals Oy With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
